GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease:

Dementia Big
Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer’s disease.

http://ift.tt/2ds6Zgi